NCT03333616 2026-01-21Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsDana-Farber Cancer InstitutePhase 2 Active not recruiting100 enrolled
NCT03212404 2025-02-03Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersCheckpoint Therapeutics, Inc.Phase 1 Active not recruiting272 enrolled 1 FDA
NCT04660929 2024-12-18CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsCarisma Therapeutics IncPhase 1 Active not recruiting48 enrolled
NCT05368207 2024-03-13Pemb-HTUniversity Health Network, TorontoPhase NA Active not recruiting1 enrolled